FDA Renews Cardiovascular and Renal Drugs Advisory Panel

Federal Register Notice: The FDA commissioner is renewing the Cardiovascular and Renal Drugs Advisory Committee for an additional two years beyond the charter expiration date. The new charter will be in effect until 8/27/18. To view this notice, click here.

Read more